The presentation of Ye Xin Koh was not recorded.
|
Date: 15 March 2022
Time: 11am - 12pm Panel discussion: "Promoting clinician-scientist collaborations in the cell therapy ecosystem" Format: Zoom Meeting (registration is required) Hosted by: Adrian Teo, IMCB & ExCo SCSS Alvin Soetedjo, IMCB |
Panelists' information
|
Xinyi SU
Institute of Molecular and Cell Biology Progress and Challenges in Retinal Cell Therapy for Vision Regeneration |
|
Abstract
This talk will cover work from retinal translational therapeutics lab on retinal stem cell transplants in non-human primate models, and unique stem cell resources we are developing in collaboration with industry partners, and includes our efforts to translate retinal stem cell therapy into an effective treatment for retinal degenerative diseases.
Bio
I am a clinician-scientist in ophthalmology, subspecializing in surgical retina and with a scientific focus on understanding how combinatorial biomaterial and retinal regenerative cell therapies can be used for the treatment of retinal degenerative disease. Currently an Assistant Professor (on tenure-track) at the National University of Singapore (NUS), I balance my time in clinical care as a Consultant Vitreo-retinal Surgeon at National University Hospital (NUHS), and lead a broad research program in retinal disease. I hold joint appointments as Senior Principal Investigator, Division Director at the Institute of Molecular and Cell Biology (IMCB, A*STAR) and Clinician-Scientist at the Singapore Eye Research Institute (SERI).
This talk will cover work from retinal translational therapeutics lab on retinal stem cell transplants in non-human primate models, and unique stem cell resources we are developing in collaboration with industry partners, and includes our efforts to translate retinal stem cell therapy into an effective treatment for retinal degenerative diseases.
Bio
I am a clinician-scientist in ophthalmology, subspecializing in surgical retina and with a scientific focus on understanding how combinatorial biomaterial and retinal regenerative cell therapies can be used for the treatment of retinal degenerative disease. Currently an Assistant Professor (on tenure-track) at the National University of Singapore (NUS), I balance my time in clinical care as a Consultant Vitreo-retinal Surgeon at National University Hospital (NUHS), and lead a broad research program in retinal disease. I hold joint appointments as Senior Principal Investigator, Division Director at the Institute of Molecular and Cell Biology (IMCB, A*STAR) and Clinician-Scientist at the Singapore Eye Research Institute (SERI).
|
Ye Xin KOH
Singapore General Hospital At the crossroads of transplantation and stem cell therapy |
|
Abstract
This talk describes my journey to combine clinical surgery and transplantation with stem cell therapy. I will share some clinical and research challenges we face in developing a bio-artificial pancreas.
Bio
I am a hepatopancreatobiliary and transplant surgeon. I trained locally in advanced minimally invasive surgery for liver and pancreatic cancers and received further training in advanced pancreatobiliary malignancies in Hokkaido University, Japan and abdominal transplantation in Addenbrooke’s Hospital, Cambridge, focusing on pancreas and multi-visceral transplantation. I hope to contribute to the eventual development of a bio-artificial pancreas as well as bio-artificial intestines.
This talk describes my journey to combine clinical surgery and transplantation with stem cell therapy. I will share some clinical and research challenges we face in developing a bio-artificial pancreas.
Bio
I am a hepatopancreatobiliary and transplant surgeon. I trained locally in advanced minimally invasive surgery for liver and pancreatic cancers and received further training in advanced pancreatobiliary malignancies in Hokkaido University, Japan and abdominal transplantation in Addenbrooke’s Hospital, Cambridge, focusing on pancreas and multi-visceral transplantation. I hope to contribute to the eventual development of a bio-artificial pancreas as well as bio-artificial intestines.
|
Dave YONG
Miltenyi Biotec Asia Pacific Pte Ltd Bridging the gap in stem cell derived therapies |
|
Abstract
Manufacturing adherent cells, such as pluripotent stem cells (PSC) and their derivatives or mesenchymal stromal cells (MSC), to GMP standards is a challenging endeavor. It involves many open handling steps and requires multiple devices, high-class cleanrooms, and well-trained operators, which can compromise reproducibility and significantly increase manufacturing costs. Relying on our widely used CliniMACS Prodigy® Cell Manufacturing Platform, we have developed the Adherent Cell Culture System. It automates GMP-compliant stem cell expansion and differentiation processes in a closed and scalable system.
Manufacturing adherent cells, such as pluripotent stem cells (PSC) and their derivatives or mesenchymal stromal cells (MSC), to GMP standards is a challenging endeavor. It involves many open handling steps and requires multiple devices, high-class cleanrooms, and well-trained operators, which can compromise reproducibility and significantly increase manufacturing costs. Relying on our widely used CliniMACS Prodigy® Cell Manufacturing Platform, we have developed the Adherent Cell Culture System. It automates GMP-compliant stem cell expansion and differentiation processes in a closed and scalable system.
BIO
Dave Yong is the Sales Team Leader for Miltenyi Biotec Asia Pacific Pte Ltd, and is aimed at enabling cell and gene therapies within the region. In the role, he developed an interest to learn and share with the community over a board range of topics, which includes both immuno-, stem cell, and non-cell based therapies. His journey began with veterinary research, and made a switch to sales and marketing role in another biotech company later on.
Dave Yong is the Sales Team Leader for Miltenyi Biotec Asia Pacific Pte Ltd, and is aimed at enabling cell and gene therapies within the region. In the role, he developed an interest to learn and share with the community over a board range of topics, which includes both immuno-, stem cell, and non-cell based therapies. His journey began with veterinary research, and made a switch to sales and marketing role in another biotech company later on.